Form 4: BlackRock BSTZ Director Sells All Direct Shares

A BlackRock Science & Technology Term Trust director reported the sale of all directly held common stock totaling 9,293.6469 shares under a pre-arranged plan.

Summary

• Robert W Fairbairn, a Director of BlackRock Science & Technology Term Trust (BSTZ), reported the sale of common stock.
• On December 18, 2025, 9,293 shares were sold at a price of $22.51 per share.
• On December 19, 2025, an additional 0.6469 shares were sold at a price of $22.73 per share.
• These transactions were conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following these sales, Robert W Fairbairn's direct beneficial ownership of common stock in BSTZ is 0 shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director selling their entire direct stake, even though it was under a pre-arranged 10b5-1 plan. While the plan mitigates the negative signal, a complete divestment of direct holdings by a director can still raise questions among investors.

Positives

• The sales were executed under a Rule 10b5-1(c) plan, indicating they were pre-scheduled and not necessarily a reaction to recent company performance or insider information.

Negatives

• A director selling their entire direct beneficial ownership (9,293.6469 shares) could be perceived negatively by investors, potentially signaling a lack of confidence, although the 10b5-1 plan mitigates this to some extent.

Future Outlook

NA

Industry Context

This is an insider transaction report. While it doesn't directly relate to broader industry trends, insider selling, even under a 10b5-1 plan, is often scrutinized by the market for potential signals about management's long-term view of the company or sector.

Stakeholder Impact

• Shareholders: May view the director's sale of all direct shares with caution, despite the 10b5-1 plan, potentially leading to questions about future stock performance or management's long-term commitment.

Key Dates

Recommendation

While a director selling their entire direct stake might typically be a 'sell' signal, the fact that these sales were executed under a pre-arranged 10b5-1 plan mitigates the immediate negative interpretation. It suggests the sales were planned in advance and not based on recent adverse developments. However, the complete divestment of direct holdings by a director still warrants caution. Without further information on the director's overall compensation structure (e.g., indirect holdings, options), or the company's fundamental performance, a 'hold' recommendation is appropriate to observe market reaction and future company developments.

Keywords

BlackRock Science & Technology Term Trust, BSTZ, Form 4, Insider Trading, Director Sale, Robert W Fairbairn, Stock Sale, 10b5-1 Plan, Beneficial Ownership